found Documents: 833

Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Jul 2020

Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China

1 item

Hong Kong, Shanghai & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administration (“NMPA”) has granted Priority Review st

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 24 Jul 2020

Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China

1 item

— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med — Hong Kong, Shanghai & Florham Park, NJ: Friday, July 24, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has in

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 8 Jul 2020

TR-1: Standard form for notification of major holdings

1 item

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Jul 2020

TR-1: Standard form for notification of major holdings

1 item

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 7 Jul 2020

Notification of Dilution of Voting Rights

1 item

London: Tuesday, July 7, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (“CK Hutchison”) shareholding1 in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par v

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jun 2020

Blocklisting Six Monthly Return

1 item

London: Monday, June 29, 2020: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limite

View Announcement (PDF)

Announcements & Press Releases, Group | 26 Jun 2020

Chi-Med to Announce 2020 Half-Year Financial Results

1 item

London: Friday, June 26, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time (BST) (7:00 p

View Announcement (PDF)

Announcements & Press Releases, Group | 25 Jun 2020

Chi-Med Announces US$100 Million Equity Investment by General Atlantic

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION – Strategic investment demonstrates General Atlant

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Jun 2020

Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer

1 item

London: Thursday, June 18, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for the development of fruquintinib, for th

Download Press Release (PDF)

Announcements & Press Releases, Other Ventures, Press Releases | 9 Jun 2020

Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement

1 item

London: Tuesday, June 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), its 50:50 joint venture with Guangzhou Baiyu

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Jun 2020

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review

1 item

London: Thursday, June 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of fruquintinib has completed a planned interim data review.

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 1 Jun 2020

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

1 item

London: Monday June 1, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) for surufatinib f

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 May 2020

Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

1 item

Press Release — First NDA filing of savolitinib globally — — Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor — London: Friday, May 29, 2020: Hutchison China MediTech Limi

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 May 2020

Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20

1 item

Press Release ― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype ― ― Savolitinib vs. sunitinib stu

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 26 May 2020

Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

1 item

Press Release – Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia – LONDON, UK; CAMBRIDGE, Mass. and BEIJING

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 May 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program

1 item

London: Thursday, May 14, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming AS

Download Press Release (PDF)

Announcements & Press Releases, Group | 11 May 2020

Chi-Med to Attend Upcoming Investor Conferences

1 item

London: Monday, May 11, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Healt

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Apr 2020

Grant of Share Options under Share Option Scheme

1 item

London: Wednesday, April 29, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on April 28, 2020, in accordance with its new incentive policy outlined in its full year results announcement on March 3, 2020, it gr

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 27 Apr 2020

Results of Annual General Meeting

1 item

London: Monday, April 27, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2020 were duly pa

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Coverage | 22 Apr 2020

Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings

1 item

London: Wednesday, April 22, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cance

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 21 Apr 2020

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme

1 item

London: Tuesday, April 21, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that on April 20, 2020, in accordance with the new incentive policy outlined in its full year results announcement on March 3, 2020, it

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Apr 2020

Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

1 item

London: Friday, April 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two Fast Track Designations for the development of surufatinib, for

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 31 Mar 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China

1 item

London: Tuesday, March 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (“FGFR”), in patients

Download Press Release (PDF)

Announcements & Press Releases, Group | 25 Mar 2020

2019 Annual Report and Notice of Annual General Meeting

1 item

London: Wednesday, March 25, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”) have bee

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 9 Mar 2020

Vesting of awards under the Long Term Incentive Plan

1 item

London: Monday, March 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) announces that following the announcement of the 2019 annual results of Chi-Med on March 3, 2020, the following awards granted under the Long Term Incen

View Announcement (PDF)

Announcements & Press Releases, Group | 3 Mar 2020

Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs

1 item

Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT London: Tuesday, March 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM), a commercial-stage biopharmaceutical comp

View Announcement (PDF)

Announcements & Press Releases, Group | 25 Feb 2020

Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions

1 item

London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesd

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Feb 2020

Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

1 item

Press Release London: Monday, February 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combi

Download Press Release (PDF)

Announcements & Press Releases, Group | 6 Feb 2020

Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 31 Jan 2020

Chi-Med to Announce 2019 Final Results

1 item

The announcement has been updated on February 25, please see the updated announcement here. London: Friday, January 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended Decem

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Jan 2020

TR-1: Standard form for notification of major holdings

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 23 Jan 2020

Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 21 Jan 2020

Chi-Med Announces Proposed Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 20 Jan 2020

Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

1 item

London: Monday, January 20, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Jan 2020

Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors

1 item

Press Release London: Monday, January 13, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (toripalimab) in patients with advanced solid tumors.

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 6 Jan 2020

Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference

1 item

Press Release London: Monday, January 6, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednes

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Dec 2019

Blocklisting Six Monthly Return

1 item

London: Tuesday, December 31, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 31 Dec 2019

Total Voting Rights

1 item

London: Tuesday, December 31, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 31, 2019, the issued share capital of Chi-Med consisted of 666,906,450 ordinary shares of US$0.10 ea

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Dec 2019

Chi-Med’s New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China

1 item

Press Release London: Friday, December 20, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (“NMPA”) has gran

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 12 Dec 2019

Grant of Share Options under Share Option Scheme

1 item

London: Thursday, December 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on December 11, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General

View Announcement (PDF)

Announcements & Press Releases, Regulatory Notice | 29 Nov 2019

Total Voting Rights

1 item

London: Friday, November 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 29, 2019, the issued share capital of Chi-Med consisted of 666,886,450 ordinary shares of US$0.10 eac

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Nov 2019

Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

1 item

London: Thursday, November 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Elunate® (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment of patients with advanced

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 25 Nov 2019

Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

1 item

London: Monday, November 25, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug designation to surufatinib for the treatment of pancr

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Nov 2019

Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting

1 item

London: Saturday, November 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shared analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress (“ESM

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 11 Nov 2019

Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

1 item

London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine

View Announcement (PDF)

Group, Press Releases | 11 Nov 2019

Chi-Med to Attend Upcoming Investor and Industry Conferences

1 item

London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the following conferences: Deutsche Bank Depositary Receipts Virt

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Oct 2019

Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

1 item

London: Thursday, October 17, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer basKeT KORea studY) trial in Ca

Download Press Release (PDF)

Announcements & Press Releases, Regulatory Notice | 10 Oct 2019

Grant of Share Options under Share Option Scheme

1 item

London: Thursday, October 10, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 9, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Me

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Oct 2019

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

1 item

Suzhou, China and London, UK, Thursday, October 10, 2019 — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration ag

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Oct 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

1 item

London: Friday, October 4, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with relapsed or refr

Download Press Release (PDF)

1 2 3 4 5 6 7

9 10 11 12 13 14 15 16 17